Literature DB >> 21821520

State of the science of cardioprotection: Challenges and opportunities--proceedings of the 2010 NHLBI Workshop on Cardioprotection.

Robert A Kloner1, Lisa Schwartz Longacre.   

Abstract

The National Heart, Lung, and Blood Institute convened a Workshop on September 20-21, 2010, "New Horizons in Cardioprotection," to identify future research directions for cardioprotection against ischemia and reperfusion injury. Since the early 1970s, there has been evidence that the size of a myocardial infarction could be altered by various interventions. Early coronary artery reperfusion has been an intervention that consistently reduces myocardial infarct size in animal models as well as humans. Most cardiologists agree that the best way to treat acute ST-segment elevation myocardial infarction is to reperfuse the infarct artery as soon as possible and to keep the infarct artery patent. In general, stenting is superior to angioplasty, which is superior to thrombolysis. There is no accepted adjunctive therapy to acutely limit myocardial infarct size along with reperfusion that is routinely used in clinical practice. In the Kloner experimental laboratory, some adjunctive therapies have reproducibly limited infarct size (regional hypothermia, preconditioning, cariporide, combinations of the above, remote preconditioning, certain adenosine agonists, and late sodium current blockade). In clinical trials, a host of pharmacologic adjunctive therapies have failed to either reduce infarct size or improve clinical outcome. Potential reasons for the failure of these trials are discussed. However, some adjunctive therapies have shown promise in data subanalyses or subpopulations of clinical trials (adenosine, therapeutic hypothermia, and hyperoxemic reperfusion) or in small clinical trials (atrial natriuretic peptide, ischemic postconditioning, and cyclosporine, the mitochondrial permeability transition pore inhibitor). A recent clinical trial with remote conditioning induced by repetitive inflation of a brachial artery cuff begun prior to hospitalization showed promise in improving myocardial salvage and there are several reports in the cardiothoracic literature, suggesting that remote preconditioning protects hearts during surgery. Thus, in 2011, there is hope that applying some of the body's own conditioning mechanisms may provide protection against ischemic damage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821520     DOI: 10.1177/1074248411402501

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  18 in total

1.  At the crossroads from bench to bedside: luteolin is a promising pharmacological agent against myocardial ischemia reperfusion injury.

Authors:  Defeng Pan; Dongye Li
Journal:  Ann Transl Med       Date:  2016-12

2.  Elucidating Mitochondrial Electron Transport Chain Supercomplexes in the Heart During Ischemia-Reperfusion.

Authors:  Sehwan Jang; Taber S Lewis; Corey Powers; Zaza Khuchua; Christopher P Baines; Peter Wipf; Sabzali Javadov
Journal:  Antioxid Redox Signal       Date:  2016-11-11       Impact factor: 8.401

Review 3.  'Combat' Approach to Cardiogenic Shock.

Authors:  Alexander G Truesdell; Behnam Tehrani; Ramesh Singh; Shashank Desai; Patricia Saulino; Scott Barnett; Stephen Lavanier; Charles Murphy
Journal:  Interv Cardiol       Date:  2018-05

Review 4.  Cardioprotection and myocardial reperfusion: pitfalls to clinical application.

Authors:  Richard S Vander Heide; Charles Steenbergen
Journal:  Circ Res       Date:  2013-08-02       Impact factor: 17.367

5.  Potent cardioprotection from ischemia-reperfusion injury by a two-domain fusion protein comprising annexin V and Kunitz protease inhibitor.

Authors:  C-H Yeh; T-P Chen; Y-C Wang; S-W Fang; T-C Wun
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

Review 6.  Mitochondrial permeability transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for cardioprotection?

Authors:  Sabzali Javadov; Sehwan Jang; Rebecca Parodi-Rullán; Zaza Khuchua; Andrey V Kuznetsov
Journal:  Cell Mol Life Sci       Date:  2017-04-04       Impact factor: 9.261

7.  Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia.

Authors:  David A Brown; Sharon L Hale; Christopher P Baines; Carlos L del Rio; Robert L Hamlin; Yukie Yueyama; Anusak Kijtawornrat; Steve T Yeh; Chad R Frasier; Luke M Stewart; Fatiha Moukdar; Saame Raza Shaikh; Kelsey H Fisher-Wellman; P Darrell Neufer; Robert A Kloner
Journal:  J Cardiovasc Pharmacol Ther       Date:  2013-11-28       Impact factor: 2.457

8.  Chronic β1-adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardium.

Authors:  Louise E See Hoe; Jan M Schilling; Anna R Busija; Kristofer J Haushalter; Victoria Ozberk; Malik M Keshwani; David M Roth; Eugene Du Toit; John P Headrick; Hemal H Patel; Jason N Peart
Journal:  Eur J Pharmacol       Date:  2016-06-30       Impact factor: 4.432

9.  Natural IgM Blockade Limits Infarct Expansion and Left Ventricular Dysfunction in a Swine Myocardial Infarct Model.

Authors:  Smita Sihag; Michael S Haas; Karen M Kim; J Luis Guerrero; Jonathan Beaudoin; Elisabeth M Alicot; Franziska Schuerpf; James D Gottschall; Robyn J Puro; Joren C Madsen; David H Sachs; Walter Newman; Michael C Carroll; James S Allan
Journal:  Circ Cardiovasc Interv       Date:  2016-01       Impact factor: 6.546

Review 10.  Ischaemic conditioning and reperfusion injury.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.